Hoffmann, Petra and Boeld, Tina J. and Eder, Ruediger and Albrecht, Julia and Doser, Kristina and Piseshka, Biserka and Dada, Ashraf and Niemand, Claudia and Assenmacher, Mario and Orsó, Evelyn and Andreesen, Reinhard and Holler, Ernst and Edinger, Matthias (2006) Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 12 (3), pp. 267-274.
Full text not available from this repository.
Other URL: http://dx.doi.org/10.1016/j.bbmt.2006.01.005
The adoptive transfer of donor CD4+CD25+ regulatory T cells has been shown to protect from lethal graft-versus-host disease after allogeneic bone marrow transplantation in murine disease models. Efficient isolation strategies that comply with good manufacturing practice (GMP) guidelines are prerequisites for the clinical application of human CD4+CD25+ regulatory T cells. Here we describe the isolation of CD4+CD25+ T cells with regulatory function from standard leukapheresis products by using a 2-step magnetic cell-separation protocol performed under GMP conditions. The generated cell products contained on average 49.5% CD4+CD25high T cells that phenotypically and functionally represented natural CD4+CD25+ regulatory T cells and showed a suppressive activity comparable to that of CD4+CD25+ regulatory T-cell preparations purified by non-GMP-approved fluorescence-activated cell sorting.
|Institutions:||Medicine > Abteilung für Hämatologie und Internistische Onkologie|
|Keywords:||Anergy; Tolerance; Suppressor T lymphocytes; Graft-versus-host disease; Good manufacturing practice|
|Subjects:||600 Technology > 610 Medical sciences Medicine|
|Refereed:||Yes, this version has been refereed|
|Created at the University of Regensburg:||Unknown|
|Deposited On:||08 Feb 2007|
|Last Modified:||20 Apr 2010 08:51|